Atlas Protocol · Clinical Prevention

Atlas Hair Resilience

Trace-derived polygenic and epigenetic read on hair-loss risk -- the visible question, with the underlying androgen-signaling, metabolic, and cardiovascular biology surfaced alongside.

Atlas Hair Resilience reads the inherited and epigenetic factors that influence hair-loss risk over time, and the biology behind them. The 389 risk loci identified in published research connect hair-loss susceptibility to broader androgen-signaling, metabolic, and cardiovascular pathways. The result is a structured report that begins with the visible question -- will my hair change, and if so, how -- and surfaces the underlying biology that links hair to wider health.

WHAT THIS TEST ANSWERS

Questions this protocol answers.

  • Do I carry inherited variants and epigenetic signatures that raise my risk of androgenetic hair loss?
  • Is my hair-loss biology likely to progress quickly, or remain stable?
  • How is my response to finasteride or minoxidil likely to be modified by my genotype?
Learn which 12 genes are analyzed

AR, EDA2R, SRD5A2, WNT10A, FGF5, EBF1, IRF4, HDAC9, TWIST1, TWIST2, DKK2, FZD10

GenDG §10

This is a predictive genetic test.

The order page will ask you to either book counseling or waive counseling in writing per German GenDG §10. Your choice is fully documented and accessible at any time.

HOW IT WORKS

How it works.

  1. 01

    Easy at-home test

    Order in three clicks, no login. Kit ships from Berlin within 5 working days.

  2. 02

    Get your report and personalized action plan

    Follow the guided sample collection. Your AI-interpreted clinical report arrives by secure email.

  3. 03

    Consult with professionals and retest

    Discuss findings with your physician or our medical geneticist; retest as your interventions evolve.

WHICH PART OF YOUR BODY

Which part of your body.

  • Scalp and hair follicles
  • Androgen-signaling pathways (brain)
  • Liver (steroid metabolism)
  • Adrenal glands (DHEA and androgen precursors)
  • Skeletal muscle (shared expression)
WHAT THIS PANEL ANSWERS

What this panel answers.

Do you carry inherited variants and epigenetic signatures that raise your risk of androgenetic hair loss, accelerate its progression, or modify your response to standard treatments such as finasteride and minoxidil?

WHAT CHANGES IF A FINDING IS IDENTIFIED

What changes if something is found.

  1. A high polygenic risk score for early-onset androgenetic hair loss can inform earlier consultation with a dermatologist or hair-specialist physician, before clinically visible thinning begins.
  2. Variants at SRD5A2, the gene encoding the target enzyme of finasteride, can inform a physician's assessment of whether standard pharmacological intervention is likely to be effective for you.
  3. Epigenetic trajectory signals from longitudinal Trace measurements can indicate whether lifestyle factors (stress, sleep, nutrition, smoking, ultraviolet exposure) are accelerating or stabilizing your hair-relevant biology over time.
  4. Hair-loss genetics are correlated with cardiovascular disease, type 2 diabetes, metabolic syndrome, and prostate health. A strong hair-loss signal can prompt earlier attention to related health domains and a broader Atlas Clinical Prevention review.
Pathway references
  • GenDG §9
GENES ANALYZED

What is analyzed.

Atlas Hair Resilience reads inherited and epigenetic factors that influence hair-loss risk from your Atlas Baseline whole-genome data. The polygenic score combines 389 published hair-loss risk loci with Trace methylation signal at hair-relevant gene regions. Named major contributors are surfaced below; the full 389-locus set is computed at report time.

Hair Resilience (polygenic + epigenetic)

389 risk loci

Polygenic risk reading across 389 published hair-loss risk loci, with named major contributors shown below. The score combines inherited variants -- on the X chromosome (AR / EDA2R) and across the autosomes (SRD5A2, WNT10A, FGF5, and many more) -- with epigenetic signal from Atlas Trace methylation at hair-relevant gene regions. The full 389-locus set is computed at report time from your Atlas Baseline data.

Clinical areas covered
  • Androgenetic hair loss -- onset, progression, treatment response
  • Androgen signaling and steroid metabolism
  • Cardiovascular and metabolic biology linked to hair-loss genetics
  • Prostate health pleiotropy
Analyzed genes -- 389 risk loci
  • AR
  • EDA2R
  • SRD5A2
  • WNT10A
  • FGF5
  • EBF1
  • IRF4
  • HDAC9
  • TWIST1
  • TWIST2
  • DKK2
  • FZD10
Limitations
  • Individual-level hair-loss prediction remains limited even with comprehensive genetic data. The strongest current models achieve approximately 73% to 83% accuracy depending on severity and age of onset. A high polygenic score indicates increased risk but does not guarantee progression; a low score does not eliminate it.

Polygenic locus set per Henne SK, Nöthen MM, Heilmann-Heimbach S. Male-pattern hair loss: Comprehensive identification of the associated genes as a basis for understanding pathophysiology. Med Genet. 2023;35(1):3-14. doi:10.1515/medgen-2023-2003.

WHY THIS MATTERS

Why early knowledge matters.

  • Hair Resilience (polygenic + epigenetic)

    Hair loss is a visible entry point into deeper systemic biology. The 389 loci identified in published GWAS connect hair-loss susceptibility to androgen signaling, metabolic pathways, cardiovascular disease, type 2 diabetes, metabolic syndrome, and prostate health. A strong hair-loss signal is a reason to look earlier at related health domains -- not only at the scalp.

RESULT INTERPRETATION

How findings are reported.

Every Atlas predictive report uses the same five-outcome framework so you and your physician can read it the same way each time.

  1. 01

    Pathogenic variant

    Increased disease risk. The report includes an individualized prevention plan and a recommendation to discuss next steps with a physician or medical geneticist.

  2. 02

    Likely pathogenic variant

    Probable disease association. Preventive monitoring is typically justified; the strength of evidence is documented in the report.

  3. 03

    Variant of uncertain significance (VUS)

    Reported but not currently actionable. A VUS may be reclassified over time as new evidence accumulates -- Atlas does not act on VUS findings without specialist review.

  4. 04

    No relevant variant in this panel

    No pathogenic or likely-pathogenic variant was identified in the analyzed genes. This does not eliminate all genetic risk -- only the genes in this panel were assessed.

  5. 05

    Family implications

    When an actionable variant is found, cascade testing of first-degree relatives is typically recommended -- a decision made together with a counselor.

Module-specific implications

  • Hair Resilience (polygenic + epigenetic)

    • A high polygenic risk score for early-onset androgenetic hair loss can inform earlier consultation with a dermatologist or hair-specialist physician, before clinically visible thinning begins.
    • Variants at SRD5A2, the gene encoding the target enzyme of finasteride, can inform a physician's assessment of whether standard pharmacological intervention is likely to be effective for you.
    • Epigenetic trajectory signals from longitudinal Trace measurements can indicate whether lifestyle factors (stress, sleep, nutrition, smoking, ultraviolet exposure) are accelerating or stabilizing your hair-relevant biology over time.
    • Hair-loss genetics correlate with cardiovascular disease, type 2 diabetes, metabolic syndrome, and prostate health -- a strong hair-loss signal can prompt earlier attention to related health domains and a broader Atlas Clinical Prevention review.
Counseling and cascade testing

Predictive genetic testing in Germany requires consultation with a physician qualified in human genetics under §7 of the GenDG (Arztvorbehalt). Atlas Counseling provides this before and after the test. When an actionable finding has implications for relatives, your counselor will discuss cascade testing -- not Atlas alone.

CLINICAL LIMITATIONS

What this test does not do.

  • Not a diagnosis of active disease

    A variant indicates predisposition. It does not confirm a condition is currently present.

  • Does not replace screening or routine care

    Imaging, lab work, and physical examination remain part of clinical care. Atlas results inform them; they do not substitute for them.

  • Not all risk is genetic

    Environment, behavior, age, and chance contribute to most common conditions. A genetic test reads one input.

  • A negative result does not eliminate risk

    Only the genes on the panel were analyzed. Variants in other genes, in non-coding regions, and outside the assay's technical scope are not assessed.

  • Clinical decisions remain with your physician

    Atlas reports are designed to be reviewed with a physician or medical geneticist. We do not recommend acting on a finding without that conversation.

GenDG §7

Predictive panels on this page are GenDG §7 Arztvorbehalt: counseling with a qualified human-genetics physician is required before and after the test. Atlas Counseling is included in the order flow.

PRICING AND BUNDLE

Two ways to read your hair.

Atlas Hair Resilience reads from Atlas Baseline whole-genome data. If you already hold Baseline, the standalone protocol reuses your existing sequencing. If you do not, the bundle includes Baseline at a combined price.

See an example Atlas Hair Resilience report →
Hair Resilience standalone
€349

Reuses your existing Atlas Baseline whole-genome data and Trace methylation signal. For customers who already hold Baseline.

Order standalone →
Hair Resilience + Atlas Baseline
€849

Includes Atlas Baseline whole-genome sequencing (saliva sample) alongside the Hair Resilience interpretation. For customers who do not yet hold Baseline.

Save €100 vs €949 separate.

Order bundle →

Stripe Payment Links for this protocol are scheduled for manual creation. The checkout button is live; the underlying Payment Link URL is swapped in once the link is created in the Stripe Dashboard.

SCIENTIFIC SOURCE

Henne SK, Nöthen MM, Heilmann-Heimbach S. Male-pattern hair loss: Comprehensive identification of the associated genes as a basis for understanding pathophysiology. Med Genet. 2023;35(1):3-14. doi:10.1515/medgen-2023-2003.

Atlas Hair Resilience polygenic scoring is informed by research from the Institute of Human Genetics at University Hospital Bonn, including work by our scientific partner Life & Brain GmbH.

Ready to start? €349 · 3–4 weeks after sample arrival

Order →

Not sure if this is the right protocol? Let Atlas walk you through a few questions. Start Triage →

Or browse all 24 protocols: Open the Console →

Not ready? Book a counseling session first →

Already have your genome with Atlas?

See Atlas Baseline